Search results
Pages
-
- The identification of small molecule inhibitors that reduce invasion and metastasis of aggressive cancers
-
- Comprehensive functional characterization and clinical interpretation of 20 splice-site variants of the RAD51C gene
-
- Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands
-
- Functional characterization of PALB2 variants of uncertain significance: toward cancer risk and therapy response prediction
-
- Reducing the risk of secondary lung cancer in treatment planning of accelerated partial breast irradiation
-
- Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort
-
- Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer
-
- The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer
-
- Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges
-
- Is There a Relationship between Shared Decision Making and Breast Cancer Patients' Trust in Their Medical Oncologists?
-
- Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer
-
- Women's Acceptance of Overdetection in Breast Cancer Screening: Can We Assess Harm-Benefit Tradeoffs?
-
- Validity and Reliability of the Japanese Version of the 10-Item Perceived Efficacy in Patient-Physician Interactions (PEPPI-10) Scale in Breast Cancer Outpatients
-
- The "Psychosocial Aspects in Hereditary Cancer" questionnaire in women attending breast cancer genetic clinics
-
- Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
-
- Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients